aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in Cleveland, NovelMed Therapeutics is a privately-held biotechnology company dedicated to developing innovative therapies for both orphan and non-orphan diseases. The company's core mission is to transform patients' lives by targeting specific parts of the immune system involved in disease processes. NovelMed specializes in complement-based therapies and offers a portfolio of neutralizing monoclonal antibodies aimed at treating acute and chronic conditions with significant market potential and unmet medical needs.
Notable affiliated individuals and investors include experienced biotech professionals and venture capitalists committed to advancing medical science. Key achievements for NovelMed include the discovery of a single therapy for both Wet-AMD and Dry-AMD, as well as pioneering first-in-class treatments for hemolytic disorders like PNH and rare kidney diseases. The company's innovative approach has had a substantial impact on the biotech industry, particularly in the development of treatments for complex and rare diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Biotechnology, Therapies
Technology
Biotech
Tags
SaaS
Model Types
Recurring
Revenue Type(s)
Enterprise
Customer Type(s)
United States
When was NovelMed Therapeutics founded?
NovelMed Therapeutics was founded in 2003.
Where is NovelMed Therapeutics’s headquarters located?
NovelMed Therapeutics’s headquarters is located in Cleveland, OH, US.
When was NovelMed Therapeutics’s last funding round?
NovelMed Therapeutics’s most recent funding round was for $1.4M (USD) in September 2013.
How many employees does NovelMed Therapeutics have?
NovelMed Therapeutics has 6 employees as of Feb 4, 2024.
How much has NovelMed Therapeutics raised to-date?
As of July 05, 2023, NovelMed Therapeutics has raised a total of $1.4M (USD) since Sep 11, 2013.
Add Comparison
Total Raised to Date
$1.4M
USD
Last Update Sep 11, 2013
Last Deal Details
$1.4M
USD
Sep 11, 2013
Grant
Total Employees Over Time
6
As of Feb 2024
NovelMed Therapeutics Address
11000 Cedar Ave
Cleveland,
Ohio
44106
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts